Mandate

Vinge advises Hansa Medical in connection with directed share issue

November 30, 2017

The board of directors of Hansa Medical has resolved on a directed new issue of ordinary shares, subject to approval by an extraordinary general meeting, whereby Hansa Medical will raise proceeds of approximately SEK 545 million, before issue costs.

The share issue is directed to a number of selected international and Swedish reputable long-only investors and international sector specialist funds, on the basis of an accelerated bookbuilding process conducted by Evercore, RBC Capital Markets and SEB.

Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Dain Hård Nevonen, Erik Sjöman, Joakim Hagberg, Sabina Börjesson and Ramin Baradaran.

The REPowerEU Plan – The EU Commission’s response to the energy market disruptions

On 18 May 2022, the EU Commission presented the REPowerEU Plan in response to the current world-wide energy market disruptions which have been caused by Russia’s invasion of Ukraine.
May 24, 2022

Sanctions update April 14

Further to our previous sanctions updates Sanctions update March 16, Sanctions Newsletter update 11 of March, Sanctions newsletter of 3 of March, Sanctions newsletter of 25 of February, we herewith provide a further update of recent sanctions developments following Russia’s war against Ukraine:
April 14, 2022

New guidance on sustainability agreements between competitors

On 1 March 2022, the European Commission published draft revised guidelines on co-operation between competitors, together with draft revised block exemption regulations for specialisation agreements and R&D agreements. Unlike the current guidelines, which expire on 31 December 2022, the new guidelines include a chapter on the assessment of so-called sustainability agreements.
April 01, 2022